DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management ...

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

TRIB stock opened at $0.64 on Wednesday. Trinity Biotech has a one year low of $0.48 and a one year high of $3.55. The firm has a 50-day moving average of $0.65 and a two-hundred day moving ...

Trinity Biotech projects an annualized run rate of $20 million in EBITDASO and $75 million in revenues by Q2 2025, with a 20% sales increase and a $6.5 million EBITDA turnaround anticipated in 2025.

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Looking for the most shorted stocks?

Trinity Biotech plc (NASDAQ:TRIB), a leading developer of diagnostic products for the healthcare industry trading near its 52-week low of $0.56, today announced a significant change in its executive ...

Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. Trinity Biotech PLC (TRIB) reports a 14% revenue increase with ...

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...